A special seminar hosted by Clifford Stein, Associate Director of Research at The Data Science Institute

Guest Speaker

Jacob Glass, MD, PhD, Medical Oncologist, Memorial Sloan Kettering Cancer Center

Details

April 2, 2021 (1:00 PM – 2:00 PM ET) – Online Event
REGISTER HERE

Hosted By

Clifford Stein, Associate Director of Research at The Data Science Institute

About the Seminar

Epigenetic and Lineage Diversity in Acute Myeloid Leukemias and MDS

Abstract: Acute leukemias are treated according to their lineage characteristics. Mixed phenotype acute leukemia (MPAL) is a rare leukemia subtype that does not fit this treatment paradigm, carrying a particularly poor prognosis. We are developing a multimodal approach to understand the biology of these and similar malignancies incorporating combined genetic/epigenetic analysis of MPAL and related cases, bioinformatic lineage deconvolution to precisely quantify lineage components, and natural language processing approaches to analyze clinical data. In addition to better characterizing MPAL, this approach has allowed us to identify distinct subsets of patients with acute myeloid leukemia and myelodysplastic syndrome with lineage infidelity.

Bio: Jacob Glass is a medical oncologist who specializes in caring for people with leukemias and myelodysplastic syndrome (MDS). I also conduct leukemia research as part of Memorial Sloan Kettering’s Center for Epigenetics Research. I continuously work to develop more-effective and more-personalized treatment approaches for people with leukemias and MDS. He has dedicated his life to better understanding the complexities of genetic and epigenetic processes in cancer. After majoring in computer science at Princeton University, he studied the epigenetic changes involved in leukemic and myelodysplastic diseases during his MD/PhD at the Albert Einstein College of Medicine in New York City. He followed this with continued epigenetic work using “big data” analytics during a residency at Weill Cornell Medical Center and throughout a fellowship at MSK.